Solute carrier family 2, facilitated glucose transporter member 4 (GLUT4) (GLUT4)

Solute carrier family 2, facilitated glucose transporter member 4, commonly known as GLUT4, is a critical protein responsible for insulin-mediated glucose uptake in skeletal muscle, cardiac muscle, and adipose tissue [UniProt: P14672]. Unlike other glucose transporters, GLUT4 is unique because it predominantly resides in intracellular vesicles under basal conditions and only translocates to the cell surface in response to insulin signaling or muscle contraction/exercise [PubMed: PMC4662203]. This translocation is a key regulatory step in maintaining systemic glucose homeostasis, as it facilitates the removal of glucose from the bloodstream after a meal [PubMed: 21257494]. Defects in GLUT4 expression or its translocation machinery are central to the development of insulin resistance and Type 2 diabetes mellitus [StatPearls: Glucose Transporters]. Therapeutically, GLUT4 is a major target for anti-diabetic medications; for instance, thiazolidinediones increase GLUT4 expression via PPAR-gamma activation, and metformin indirectly promotes its translocation to improve insulin sensitivity [PubChem: CID 4837]. Conversely, certain drugs like HIV protease inhibitors (e.g., Indinavir) can inadvertently inhibit GLUT4 function, leading to secondary metabolic complications such as hyperglycemia and lipodystrophy [PubMed: 11033012]. Monitoring and modulating GLUT4 activity remains a primary focus in the management of metabolic disorders and obesity-related health issues.

Other names

SLC2A4Glucose transporter type 4Insulin-responsive glucose transporter

Drugs targeting this molecule primarily act by enhancing the translocation of the transporter from intracellular storage vesicles to the plasma membrane or by increasing its gene expression to improve peripheral glucose uptake and reduce hyperglycemia.